Summit Therapeutics Share Discussion Threads

[kirk 6] 07/10/2019 13:20

The news gets better everyday

[chrisatrdg] 07/10/2019 13:19

I am currently listening to the broadcast very powerful.

Edit: Clearly we have a positive reaction on the NASDAQ pre open.

Edit : Current slides I think are new very powerful.

[someuwin] 07/10/2019 13:06

Summit Therapeutics plc Summit Therapeutics Reports New Data From Phase 2 Clinical Trial Connecting Ridinilazole's Microbiome...

07/10/2019 12:00pm

UK Regulatory (RNS & others)


TIDMSUMM

Summit Therapeutics plc

('Summit' or the 'Company')

Summit Therapeutics Reports New Data from Phase 2 Clinical Trial
Connecting Ridinilazole's Microbiome Preservation to Improved Clinical
Outcomes for Patients with C. difficile Infection


-- Data Presented at ID Week 2019


Oxford, UK, and Cambridge, MA, US, 7 October 2019 -- Summit Therapeutics
plc (NASDAQ: SMMT, AIM: SUMM) today announced the presentation of new
data that explain the link between two key findings in the Company's
Phase 2 clinical trial of ridinilazole for C. difficile infection
('CDI'):


-- Ridinilazole demonstrated superior efficacy compared to vancomycin,
driven by a 60% lower recurrence rate.

-- Ridinilazole preserved the diversity of the gut microbiome.


Researchers at Tufts University, collaborating with Summit, showed that
these findings are connected mechanistically by bile acids, part of the
'metabolome' of active chemicals made or modified by gut bacteria. Bile
acids exist in different forms that can either favour or block the
regrowth of C. difficile after treatment. Vancomycin kills bacteria that
turn pro-C. difficile bile acids into anti-C. difficile bile acids --
leaving an adverse ratio of pro- and anti-growth chemicals that favours
the regrowth of C. difficile and the recurrence of C. difficile
infection. By contrast, ridinilazole leaves these bacteria unharmed,
allowing them to keep converting pro-C. difficile bile acids into
anti-C. difficile bile acids, maintaining a positive chemical balance
that prevents C. difficile recurrence.

"The damaging effect of broad-spectrum antibiotics in the treatment of
CDI is far-reaching from the make-up and function of the gut microbiome
through the poor clinical outcomes seen in one third of patients, driven
by a high rate of disease recurrence," said Dr David Roblin, President
of R&D of Summit. "Ridinilazole has the potential to be a targeted CDI
treatment that could result in significantly better patient outcomes for
the over half million US patients per year who have an episode of CDI.
These latest data help to put the science behind the function of a
healthy microbiome into context and highlight its importance in
sustaining CDI cures."

The Phase 2 clinical trial enrolled 100 patients, half of whom received
ridinilazole and the other half vancomycin. For both groups, there was a
higher ratio of pro-C. difficile to anti C.-difficile bile acids at the
start of treatment. This was expected, as patients who get CDI have
perturbed microbiomes. However, during treatment, the proportion of
anti-C. difficile bile acids increased in patients treated with
ridinilazole, whereas patients treated with vancomycin initially showed
decreases in anti-C. difficile bile acids and had stools dominated by
pro-C. difficile bile acids. By the end of treatment,
ridinilazole-treated patients' bile acid ratios returned towards a
healthy, non-CDI state. These results support the data from the Phase 2
clinical trial, in which patients receiving ridinilazole showed a
statistically significant improvement in sustained clinical responses.

Copies of the two poster presentations are available in the Publications
section of Summit's website,

www.summitplc.com.

[kirk 6] 04/10/2019 21:27

Very nice close over on the Nasdaq with one of the most bullish candle stocks you can get! Equivalent about 29-30p so should be a good day Monday here. Reckon we are now on a platform for a major move higher with all the piped up good news recently and potential minimal dilution all the way to commercialisation

[kirk 6] 03/10/2019 18:12

Moving nicely now

[kirk 6] 03/10/2019 13:08

Very bullish

[fillipe] 03/10/2019 12:19

RNS 12 noon. today.



f

[waterloo01] 03/10/2019 12:10

Remarkable timing. Well done.

[markth126] 03/10/2019 12:06

well timed

[leedslad001] 03/10/2019 11:47

Hi all bought a few today

[chrisatrdg] 02/10/2019 20:12

I agree with waterloo01 & have just posted the following on the other board:

The following sentiment could be one of the reasons in the sudden share price increase for which I note further interest on the NASDAQ this evening;

Summit Therapeutics' Upcoming R&D Day Could Be A Tradeable Event:

[waterloo01] 02/10/2019 19:36

Indeed, although it's opinion, not news but welcome non the less

[kirk 6] 02/10/2019 19:02

Now that is brilliant news

[waterloo01] 02/10/2019 18:56

Summary
October's R&D day should include new Phase 2 data for the company's lead candidate ridinilazole.

The stage could be set for an update to the company's much anticipated SMT-571 candidate.

Summit Therapeutics' cash and grants mean minimal shareholder dilution before commercialization if its products gain approval.

[waterloo01] 02/10/2019 18:21

Nice to see it up 5% on Nasdaq on such a poor market day.

[kirk 6] 01/10/2019 16:31

It was 30p to buy only 1000 shares

[waterloo01] 01/10/2019 16:29

25% up non too shabby. They are looking for shares as they would take a large number over the bid, so £100k buyer around.

ID week starts tomorrow although would be surprised if the rise is connected.

[waterloo01] 01/10/2019 10:02

Maybe a middday RNS? Last time we saw this sort of volume we had a leak on Barda funding. Given results are due any day and funding must be high up the agenda, hopefully it portends some good news?

[kirk 6] 01/10/2019 08:28

What a bargain added a chunk to get my holding over 1.4m now

[kirk 6] 01/10/2019 07:58

Let's see if this gets to the 30p equivalent today

[kirk 6] 30/9/2019 21:17

*7 times the daily average

[kirk 6] 30/9/2019 21:16

Volume 5 times daily average and closed up over 16%

[algernon2] 30/9/2019 19:57

Yes indeed Waterloo has spoken for the silent majority there.
Next year Waterloo the coffee is on me.

[waterloo01] 30/9/2019 19:06

Half decent volume as well. 150k shares equivalent. Kirk, there are more than you think as most I know rarely post.

[kirk 6] 30/9/2019 18:59

I see there is only a couple of shareholders left here to enjoy the rise.Best way ...once the herd arrives ....